The company reported consolidated revenue of ₹2,270 crore for Q1FY27, with margin expansion to 12.5% and growth across CDMO, complex hospital generics and consumer healthcare.
Piramal Pharma Limited reported stronger first-quarter operating performance for the period ended June 30, 2026, as consolidated revenue from operations rose 17% year-on-year to ₹2,270 crore from ₹1,934 crore and EBITDA climbed 72% to ₹285 crore from ₹165 crore. EBITDA margin widened to 12.5% from 8.5%, which the company attributed to higher capacity utilization, operating leverage, pricing discipline and operational execution. The business posted growth across all three segments. CDMO (contract development and manufacturing organization) revenue increased 19% to ₹1,187 crore from ₹997 crore, while CHG and PCH also advanced. Piramal said its Sellersville facility in the US received an EIR (Establishment Inspection Report) from the US FDA (U.S. drug regulator), concluding the inspection, and that it has maintained Zero OAI status, referring to no official action indicated. PAT before exceptional item was a loss of ₹69 crore versus a loss of ₹102 crore a year earlier. PAT after exceptional item was a loss of ₹82 crore. The company noted that exceptional items in Q1FY26 included one-time insolvency proceeds received from a claim filed against a third-party supplier of its complex hospital generics business with the NCLT (India insolvency tribunal) in November 2023. Chairperson Nandini Piramal said all three businesses delivered mid-to-high teens revenue growth and meaningful EBITDA margin expansion, adding that the company expects sustained revenue growth and EBITDA expansion through FY27 while remaining agile in a dynamic external environment.